GlassScriptPhysician profile
Adam Jacobs
NPI 1689293151
$7,903.19
in general payments reported to CMS, 2019-2025
26 companies · $3,251 in 2025
The $3,251 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2023: $1,378 · 2024: $3,129 · 2025: $3,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,494 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,494.41 |
| Education | $263.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,534.83 | 2023-2025 | |
| Amgen INC. | $1,318.54 | 2023-2025 | Evenity, Tavneos, Enbrel |
| Abbvie INC. | $1,133.22 | 2024-2025 | |
| Janssen Biotech, INC. | $849.87 | 2023-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $554.38 | 2023-2025 | Saphnelo, Fasenra |
| Ucb, INC. | $542.18 | 2023-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $402.96 | 2023-2025 | Benlysta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.59 | 2023-2025 | Ofev |
| Sobi, INC | $208.00 | 2023-2025 | Kineret |
| Mallinckrodt Hospital Products INC. | $153.09 | 2024-2025 | Acthar |
| Lilly USA, LLC | $138.58 | 2024-2025 | Taltz |
| Boston Scientific Corporation | $97.44 | 2022 | |
| Kyowa Kirin, INC. | $88.38 | 2025 | |
| Janssen Scientific Affairs, LLC | $86.70 | 2024 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $84.46 | 2024-2025 | Idacio, Tyenne |
| Radius Health, INC. | $73.88 | 2024-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $51.32 | 2025 | |
| Sandoz INC. | $49.80 | 2023-2025 | Hyrimoz, Jubbonti |
| Alvogen INC | $48.69 | 2025 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $47.36 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.50 | 2025 | Sovuna |
| Kiniksa Pharmaceuticals International, Plc | $24.72 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $21.97 | 2025 | Opsumit |
| Horizon Therapeutics Plc | $14.43 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $14.31 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.